Citius Oncology (CTOR) Invested Capital (2021 - 2026)

Citius Oncology (CTOR) has reported Invested Capital for 6 consecutive years, with $44.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital rose 22.06% year-over-year to $44.2 million in Q2 2026; TTM through Jun 2026 was $44.2 million, a 22.06% increase from a year earlier, with the FY2025 full-year figure at $52.5 million, up 5.06% from the prior year.
• Invested Capital was $44.2 million for Q2 2026 at Citius Oncology, up from $39.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $62.2 million in Q4 2025 and troughed at $345508.0 in Q4 2022.
• A 5-year average of $36.1 million and a median of $39.1 million in 2026 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital surged 6859.39% in 2023 and fell 0.95% in 2026, its largest moves.
• Over 5 years, Invested Capital stood at $345508.0 in 2022, then surged by 6859.39% to $24.0 million in 2023, then soared by 87.52% to $45.1 million in 2024, then soared by 37.98% to $62.2 million in 2025, then declined by 28.98% to $44.2 million in 2026.
• The last three Invested Capital figures came in at $44.2 million (Q2 2026), $39.1 million (Q1 2026), and $62.2 million (Q4 2025), per Business Quant data.